Is the price fair?
What TDOC's price assumes
Today's price asks for −13% free cash flow growth a year; over the last three years Teladoc Health, Inc. delivered 8.5%, less than the record.
0.39
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 19%
Free cash flow yield · Health Information Services median 5.9%
- Growth the price implies
- −13%
Growth the price implies · The price pays for −13% free cash flow growth a year for a decade; the business has delivered +8.5% a year over the last three.
- Price / book
- 0.73
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 0.73
- EV / EBIToperating margin −8.1%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $280M
- Market capitalisation
- $1.46B
- 3-year free cash flow growth
- +8.5%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Health Information Services
Ranks #5 of 14 by Smart Score